# Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes

> **NCT02081599** · PHASE4 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 148 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Teneli (Teneligliptin)
- **DRUG:** Placebo
- **DRUG:** Insulin

## Key facts

- **NCT ID:** NCT02081599
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02081599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02081599, "Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02081599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*